Product image of Granisetron Kabi (Granisetron Hydrochloride) supplied by GNH India

Granisetron Kabi

Active Ingredient:
Granisetron Hydrochloride
Origin:
EU

Granisetron Kabi (Granisetron Hydrochloride)

Granisetron Kabi is a prescription injectable solution that contains the active ingredient granisetron hydrochloride; the specific strength is not disclosed in the product listing. It belongs to the 5‑HT3 receptor antagonist class and is administered intravenously to help manage nausea and vomiting associated with certain medical procedures. It is marketed in the European Union and is used under medical supervision for antiemetic therapy in adult patients.

Manufacturer / TM Owner

Fresenius Kabi Romania Srl

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granisetron Kabi is indicated for the prevention of nausea and vomiting in specific clinical settings.

  • Prevention of chemotherapy‑induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic cancer treatments.
  • Prevention of postoperative nausea and vomiting (PONV) following surgical procedures that require general anesthesia.
  • Adjunct therapy for radiation‑induced nausea when used in combination with other antiemetics.
  • Use in patients who have not responded adequately to other 5‑HT3 antagonists.

Side Effects

The safety profile of Granisetron Kabi includes both common and less frequent adverse reactions.

Common

  • Headache
  • Constipation
  • Diarrhea
  • Fatigue
  • Dizziness
  • Injection site pain
  • Dry mouth

Serious

  • Severe allergic reaction (anaphylaxis)
  • Cardiac arrhythmia
  • QT interval prolongation
  • Severe hypotension

Precautions & Warnings

Before using Granisetron Kabi, clinicians should consider several precautionary factors to ensure safe administration.

  • Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists.
  • Use caution in patients with known cardiac conduction disorders or prolonged QT interval.
  • Evaluate electrolyte balance, especially potassium, magnesium, and calcium levels, as abnormalities may increase cardiac risk.
  • Consider dose adjustment or monitoring in patients with hepatic impairment.
  • Avoid use in pregnant women unless the potential benefit justifies the risk, as safety data are limited.
  • Monitor for signs of serotonin syndrome when combined with serotonergic agents.

Avoid Interactions

Granisetron Kabi may interact with other medications; awareness of these interactions helps prevent adverse effects.

Avoid

  • Concurrent use with other 5‑HT3 receptor antagonists, which can increase the risk of cardiac toxicity.
  • Co‑administration with drugs known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics).

Use with caution

  • Serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs) or tramadol, due to potential serotonin syndrome.
  • Anticholinergic medications that may exacerbate constipation.
  • CYP3A4 inhibitors or inducers, which could affect granisetron metabolism.

Frequently Asked Questions

Granisetron Kabi works as a selective antagonist of the serotonin 5‑HT3 receptor, blocking the signaling pathway that triggers nausea and vomiting.

The medication is supplied as an injectable solution and is given intravenously by a healthcare professional.

It is used for both moderately and highly emetogenic chemotherapy regimens, such as those involving cisplatin, cyclophosphamide, or anthracyclines.

The product is primarily indicated for adult use; pediatric application should follow specific clinical guidelines and physician judgment.

Common adverse effects include headache, constipation, diarrhea, fatigue, dizziness, injection‑site pain, and dry mouth.

Granisetron Kabi is formulated as an injectable solution for intravenous use, whereas some other 5‑HT3 antagonists are available in oral or transdermal forms.

Combination therapy may be used under medical supervision, but clinicians should avoid using multiple 5‑HT3 antagonists together due to increased cardiac risk.

Monitoring includes assessment for allergic reactions, cardiac rhythm (especially QT interval), and evaluation of electrolyte levels in at‑risk patients.

Patients with known prolonged QT interval or other significant cardiac conduction abnormalities should be evaluated carefully before administration.

The injectable solution should be kept in its original container, protected from light, and stored at controlled room temperature as specified by the manufacturer.

The pregnancy safety category is listed as unknown; use only if the potential benefit justifies the potential risk to the fetus.

Serotonin syndrome is rare but may occur when Granisetron Kabi is used with other serotonergic agents; clinicians should monitor for symptoms.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT